Breast Cancer

MD IQ

Conference Coverage

Finally, immunotherapy shows benefit in TNBC

MUNICH – Adding atezolizumab to nab-paclitaxel improved progression-free and overall survival in patients with PD-L1 positive triple-negative...

Pages